Kim R. Tsuchimoto - Mar 31, 2022 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Financial Officer
Signature
/s/ Kim R. Tsuchimoto
Stock symbol
MNPR
Transactions as of
Mar 31, 2022
Transactions value $
-$1,275
Form type
4
Date filed
4/1/2022, 05:28 PM
Previous filing
Feb 4, 2022
Next filing
Jul 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +1.22K +24.84% 6.14K Mar 31, 2022 Direct F1
transaction MNPR Common Stock Tax liability -$1.28K -500 -8.15% $2.55 5.64K Mar 31, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -1.22K -1.55% $0.00 77.4K Mar 31, 2022 Common Stock 1.22K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.